{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:47:03Z","timestamp":1791150423284,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"vor","delay-in-days":5474,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2001]]},"DOI":"10.1046\/j.1469-0691.2001.00054.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:25:53Z","timestamp":1047367553000},"page":"8-15","source":"Crossref","is-referenced-by-count":80,"special_numbering":"S4","title":["The VISA\/GISA problem: therapeutic implications"],"prefix":"10.1016","volume":"7","author":[{"given":"J.","family":"Li\u00f1ares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1469-0691.2001.00054.x_bib1","series-title":"Principles and practice of infections diseases","first-page":"1754","article-title":"Staphylococcus aureus (including toxic shock syndrome)","author":"Waldvogel","year":"1995"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.1.5219.124-a","article-title":"\u2018Celbenin'-resistant staphylococci","volume":"1","author":"Jevons","year":"1961","journal-title":"Br Med J"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib3","series-title":"Hospital epidemiology and infection control","first-page":"290","article-title":"Methicillin-resistant Staphylococcus aureus","author":"Hartstein","year":"1986"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(97)00027-7","article-title":"Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices?","volume":"9","author":"Schmitz","year":"1997","journal-title":"Int J Antimicrob Agents"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2307\/30148460","article-title":"Methicillin-resistant Staphylococcus aureus in US hospitals, 1975\u201391","volume":"13","author":"Panlilio","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/BF02026127","article-title":"Methicillin resistance in Europe","volume":"13","author":"Voss","year":"1994","journal-title":"Eur J Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib7","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/JCM.32.9.2081-2087.1994","article-title":"Spread and maintenance of a dominant methicillin-resistant Staphylococcus aureus (MRSA) clone during an outbreak of MRSA disease in spanish hospital","volume":"32","author":"Dominguez","year":"1994","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJM198704093161507","article-title":"Emergence of vancomycin resistance in coagulase-negative staphylococci","volume":"316","author":"Schwalbe","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/162.1.103","article-title":"Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis","volume":"162","author":"Kaatz","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF01963643","article-title":"Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin","volume":"9","author":"Brunet","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib11","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)64269-9","article-title":"Vancomycin-resistant Staphylococcus aureus: apocalypse now?","author":"Tabaqchali","year":"1997","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/jac\/42.3.289","article-title":"Intermediate vancomycin resistance in Staphylococcus aureus: a major threat or a minor inconvenience?","volume":"42","author":"Johnson","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1469-0691.2000.00130.x","article-title":"Glycopeptide-intermediate Staphylococcus aureus. rediscovery of an old problem?","volume":"6","author":"Cercenado","year":"2000","journal-title":"Clin Microbiol Infection"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib16","first-page":"765","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin\u2014United States 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib17","first-page":"813","article-title":"Update: Staphylococcus aureus with reduced susceptibility to vancomycin\u2014United States 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib18","first-page":"624","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin\u2014Japan States 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib19","first-page":"1165","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin\u2014Illinois, 1999","volume":"48","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199902183400704","article-title":"The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection","volume":"340","author":"Sieradzki","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-intermediate and resistant Staphylococcus aureus: what the infectious disease specialist needs to know","volume":"32","author":"Fridkin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(05)79166-2","article-title":"First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital","volume":"351","author":"Ploy","year":"1998","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/bmj.318.7184.626","article-title":"Vancomycin resistant staphylococcus reported in Hong Kong","volume":"318","author":"McManus","year":"1999","journal-title":"BMJ"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib25","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/JCM.38.10.3879-3881.2000","article-title":"Vancomycin intermediate Staphylococcus aureus in Korea","volume":"38","author":"Mi-Na","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib26","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/AAC.37.11.2432","article-title":"Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex","volume":"37","author":"Shlaes","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/infdis\/166.5.1066","article-title":"Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility","volume":"166","author":"Daum","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1574-6968.1996.tb08424.x","article-title":"A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus","volume":"142","author":"Sieradzki","year":"1996","journal-title":"FEMS Microbiol Lett"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1368-7646(98)80029-0","article-title":"Vancomycin resistance in staphylococci","volume":"1","author":"Hiramatsu","year":"1998","journal-title":"Drug Resistance Updates"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib30","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0002-9343(98)00149-1","article-title":"The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan","volume":"104","author":"Hiramatsu","year":"1998","journal-title":"Am J Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1128\/AAC.44.2.272-277.2000","article-title":"Reversion of glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates","volume":"44","author":"Boyle-Vavra","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/42.2.199","article-title":"Activated cell-wall syntesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus strains Mu3 and Mu50","volume":"42","author":"Hanaki","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib33","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/jb.179.8.2557-2566.1997","article-title":"Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus","volume":"179","author":"Sieradzki","year":"1997","journal-title":"J Bacteriol"},{"issue":"Suppl. A","key":"10.1046\/j.1469-0691.2001.00054.x_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/39.suppl_1.47","article-title":"Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotic","volume":"39","author":"Sieradzki","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/mdr.1998.4.159","article-title":"Suppression of glycopeptide resistance in a highly teicoplanin resistant mutant Staphylococcus aureus by transposon inactivation of genes involved in cell wall syntesis","volume":"4","author":"Sieradzki","year":"1998","journal-title":"Microb Drug Resist"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib36","doi-asserted-by":"crossref","first-page":"18942","DOI":"10.1074\/jbc.274.27.18942","article-title":"Inactivated pbp4 in highly glycopeptide-resistant laboratory mutants of Staphylococcus aureus","volume":"274","author":"Sieradzki","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/mdr.1999.5.253","article-title":"Inactivation of the methicillin resistance gene mecA in vancomycin-resistant Staphylococcus aureus","volume":"5","author":"Sieradzki","year":"1999","journal-title":"Microb Drug Resist"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/jac\/42.3.315","article-title":"Hiramatsu. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistance Staphylococcus aureus strain Mu50","volume":"42","author":"Hanaki","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1574-6968.1992.tb05089.x","article-title":"Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS","volume":"72","author":"Noble","year":"1992","journal-title":"Microbiol Lett"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib40","series-title":"Antibiotic Annual 1955\u20131956","first-page":"90","article-title":"Some laboratory and clinical experience with a new antibiotic, vancomycin","author":"Geraci","year":"1956"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib41","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th edn. Approved standard M7-A5","author":"National Committee for Clinical Laboratory Standards","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib42","first-page":"73","article-title":"Recommendations from MENSURA for selection of antimicrobial agents for susceptibility testing and criteria for the interpretation of antibiograms","volume":"13","author":"Mesa Espa\u00f1ola de Normalizaci\u00f3n de la Sensibilidad y Resistencia a los Antimicrobianos (MENSURA)","year":"2000","journal-title":"Rev Esp Quimioterap"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib43","first-page":"1","article-title":"Comit\u00e9 de l'Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie Communiqu\u00e9","volume":"46","year":"1998","journal-title":"Pathol Biol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0195-6701(98)90293-6","article-title":"Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals","volume":"39","author":"British Society for Antimicrobial Chemotherapy","year":"1998","journal-title":"J Hosp Infect"},{"issue":"S","key":"10.1046\/j.1469-0691.2001.00054.x_bib45","first-page":"13","article-title":"Antimicrobial susceptibility testing in Sweden","volume":"105","author":"Olsson-Iiljequist","year":"1997","journal-title":"Scand J Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0196-4399(00)88583-9","article-title":"VRSA, VISA and GISA. the dilemma behind the name game","volume":"22","author":"Tenover","year":"2000","journal-title":"Clin Microbiol Newsletter"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib47","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(99)01017-X","article-title":"Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin","volume":"353","author":"Ariza","year":"1999","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib48","series-title":"Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"110","article-title":"Methicillin-resistant (MR) Staphylococcus aureus (SA) with reduced susceptibilities to glycopeptides in a Spanish hospital. [abstract C-143]","author":"Li\u00f1ares","year":"1998"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib49","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/171.6.1646","article-title":"Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus","volume":"171","author":"Mainardi","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s100960050380","article-title":"Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany","volume":"18","author":"Bierbaum","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jac\/41.5.578","article-title":"Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus","volume":"41","author":"Fitch","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib52","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/jac\/43.6.846","article-title":"Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the Dusseldorf area","volume":"43","author":"Geisel","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib53","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1128\/JCM.38.8.2985-2988.2000","article-title":"Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital","volume":"38","author":"Guerin","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib54","series-title":"Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"651","article-title":"Infections and colonizations due to methicillin-resistant Staphylococcus aureus with decreased-susceptibility to glycopeptides (GISA) in a medical intensive care unit (ICU) [session 204 K, paper 2038]","author":"Kac","year":"1999"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jac\/43.5.729","article-title":"Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus","volume":"43","author":"Kantzanou","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib56","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1198-743x.2001.00256.x","article-title":"Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals","volume":"7","author":"Reverdy","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1128\/JCM.38.2.866-869.2000","article-title":"Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital","volume":"38","author":"Marchese","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1128\/JCM.39.2.591-595.2001","article-title":"First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand","volume":"39","author":"Trakulsomboon","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib59","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/520429","article-title":"Bacteremia caused by staphylococci with inducible vancomycin heteroresistance","volume":"29","author":"Wong","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib60","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","article-title":"Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides","volume":"36","author":"Tenover","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib61","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/44.5.675","article-title":"Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus","volume":"44","author":"Howe","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib62","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/JCM.37.11.3590-3593.1999","article-title":"Glycopeptide-intermediate Staphylococcus aureus. evaluation of a novel screening method and results of a survey","volume":"37","author":"Hubert","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 3","key":"10.1046\/j.1469-0691.2001.00054.x_bib63","first-page":"113","article-title":"Micro-method conditions are optimal for detecction of low level glycopeptide resistance in Staphylococci","volume":"5","author":"Bomstr\u00f6m","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib64","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.35.1.124","article-title":"Stable classes of phenotpic expression in methicillin-resistant clinical isolates of staphylococci","volume":"35","author":"Tomasz","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-200161010-00001","article-title":"Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance. Clinical significance and treatment options","volume":"61","author":"Rybak","year":"2001","journal-title":"Drugs"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3201\/eid0501.990118","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia","volume":"5","author":"Rotun","year":"1999","journal-title":"Emerging Infect Dis"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib67","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"106","article-title":"Emergence of methicillin resistant Staphylococcus aureus (MTRSA) with decreades susceptibility to vancomycin in a Belgian Hospital [abstract 1779]","author":"Denis","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(05)78597-4","article-title":"Vancomycin resistant Staphylococcus aureus","volume":"351","author":"Howe","year":"1998","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib69","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/jac\/45.6.887","article-title":"Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals","volume":"45","author":"Chesneau","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib70","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(98)00148-X","article-title":"The specter of glycopeptide resistance: current trends and future considerations","volume":"104","author":"Moellering","year":"1998","journal-title":"Am J Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib71","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.34.6.1227","article-title":"Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users","volume":"34","author":"Small","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib72","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow reponse to vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib73","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1128\/JCM.37.9.3068-3071.1999","article-title":"Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying phenotypes of vancomycin susceptibility","volume":"37","author":"Howe","year":"1999","journal-title":"J Clin Microbiolt"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib74","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","article-title":"Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin","volume":"43","author":"Climo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib75","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1128\/AAC.43.10.2565","article-title":"Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam","volume":"43","author":"Backo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. A","key":"10.1046\/j.1469-0691.2001.00054.x_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/44.suppl_1.11","article-title":"Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin\/dalfopristin","volume":"44","author":"Pechere","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib77","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1128\/AAC.39.7.1419","article-title":"Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant Staphylococcus aureus with RP59500","volume":"39","author":"Entenza","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib78","series-title":"Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"56","article-title":"Efficacy os Synercid (SYN) and\/or cefpirome (CP) in the treatment (Rx) of experimental endocarditis (EE) due to glycopepetide intermediate Staphylococcus aureus (GISA). [abstract 1003]","author":"Vouillamoz","year":"2000"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib79","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.44.7.1925-1929.2000","article-title":"In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and\/or combination against glycopeptide-intermediate resistant Staphylococcus aureus in an infection model","volume":"44","author":"Akins","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib80","first-page":"626","article-title":"Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR"},{"key":"10.1046\/j.1469-0691.2001.00054.x_bib81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/514646","article-title":"Vancomycin-resistant of Staphylococcus aureus infection control considerations","volume":"27","author":"Wenzel","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15301117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T22:13:49Z","timestamp":1580940829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15301117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":81,"alternative-id":["S1198743X15301117"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2001.00054.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2001]]}}}